Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

BACKGROUND: Arginine-depleting therapy with pegylated arginine deiminase (ADI-PEG20) was reported to have activity in advanced melanoma in early phase I–II trial, and clinical trials are currently underway in other cancers. However, the optimal patient population who benefit from this treatment is u...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Feun, L G, Marini, A, Walker, G, Elgart, G, Moffat, F, Rodgers, S E, Wu, C J, You, M, Wangpaichitr, M, Kuo, M T, Sisson, W, Jungbluth, A A, Bomalaski, J, Savaraj, N
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2012
Teme:
Translational Therapeutics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3341859/
https://ncbi.nlm.nih.gov/pubmed/22472884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.106
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki